Royce & Associates LP Bluebird Bio, Inc. Transaction History

Royce & Associates LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$27.5 - $37.92 $165,000 - $227,520	-6,000 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$34.44 - $43.75 $654,360 - $831,250	-19,000 Reduced 76.0%	6,000 $324,000
Q2 2020 Aug 07, 2020	BUY	$27.12 - $45.97 $162,720 - $275,820	6,000 Added 31.58%	25,000 $1.53 Million
Q4 2019 Feb 06, 2020	BUY	$46.96 - $61.67 $892,240 - $1.17 Million	19,000 New	19,000 $1.67 Million
Q4 2018 Feb 11, 2019	SELL	$59.1 - $93.26 $591,000 - $932,600	-10,000 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$99.64 - $127.59 $996,400 - $1.28 Million	10,000 New	10,000 $1.57 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

Stay updated on Royce & Associates LP with notifications on news.